

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9939)

**VOLUNTARY ANNOUNCEMENT
DOSING OF FIRST PATIENT FOR ACNE VULGARIS PHASE II
CLINICAL TRIAL OF KX-826 IN CHINA**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that on 24 January 2022, the Company has enrolled and dosed the first patient in its phase II clinical trial of pyrilitamide (“**KX-826**”), its in-house developed and potential first-in-class topical drug globally, in China for the treatment of acne vulgaris.

The clinical trial of KX-826 in China for the treatment of acne vulgaris was a fusion design of phase I and phase II clinical trial. The phase II clinical trial is a multi-regional, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of KX-826 (gel) in 160 patients with mild to moderate acne vulgaris (including male and female). The primary endpoint is the treatment success rate (based on the Investigator Global Assessment – IGA score) at the end of week 12. The clinical trial will be carried out in 6 sites across China. Professor Xiang Leihong from Huashan Hospital affiliated to Fudan University is the leading principal investigator (leading PI).

The phase I clinical trial of KX-826 for the treatment of acne vulgaris has been completed and demonstrated a preliminary positive safety and tolerability profile in terms of dose-escalation and dosing frequency.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that pyrilitamide will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 24 January 2022

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*